IFM Investors Pty Ltd reduced its position in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 0.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,013 shares of the biotechnology company’s stock after selling 247 shares during the period. IFM Investors Pty Ltd’s holdings in Biogen were worth $6,593,000 at the end of the most recent quarter.
A number of other hedge funds have also recently made changes to their positions in BIIB. Kingswood Wealth Advisors LLC bought a new position in Biogen in the first quarter valued at $336,000. Sunbelt Securities Inc. increased its stake in Biogen by 106.9% in the first quarter. Sunbelt Securities Inc. now owns 627 shares of the biotechnology company’s stock valued at $135,000 after acquiring an additional 324 shares during the last quarter. Atticus Wealth Management LLC bought a new position in Biogen in the first quarter valued at $43,000. Financial Partners Group LLC bought a new position in Biogen in the first quarter valued at $226,000. Finally, Diversified Trust Co increased its stake in Biogen by 85.1% in the first quarter. Diversified Trust Co now owns 20,860 shares of the biotechnology company’s stock valued at $4,498,000 after acquiring an additional 9,588 shares during the last quarter. 87.93% of the stock is currently owned by hedge funds and other institutional investors.
Biogen Price Performance
BIIB stock opened at $181.69 on Friday. The firm has a 50 day moving average price of $195.69 and a 200-day moving average price of $210.29. Biogen Inc. has a 52-week low of $181.24 and a 52-week high of $268.30. The firm has a market capitalization of $26.46 billion, a price-to-earnings ratio of 22.88, a PEG ratio of 1.87 and a beta of -0.06. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.48 and a current ratio of 2.29.
Insider Activity at Biogen
In other Biogen news, insider Priya Singhal sold 431 shares of Biogen stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $204.22, for a total value of $88,018.82. Following the completion of the sale, the insider now owns 5,316 shares of the company’s stock, valued at approximately $1,085,633.52. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.16% of the stock is owned by insiders.
Analysts Set New Price Targets
A number of research analysts recently commented on the company. Piper Sandler reduced their target price on Biogen from $335.00 to $313.00 and set an “overweight” rating on the stock in a research note on Friday, July 12th. UBS Group reduced their price objective on Biogen from $234.00 to $202.00 and set a “neutral” rating on the stock in a research note on Thursday, October 3rd. Mizuho reduced their price objective on Biogen from $277.00 to $251.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 6th. Royal Bank of Canada reduced their price objective on Biogen from $292.00 to $269.00 and set an “outperform” rating on the stock in a research note on Friday, October 4th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $292.00 price objective on shares of Biogen in a research note on Monday, September 9th. Nine equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $271.39.
Check Out Our Latest Analysis on BIIB
About Biogen
Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.
See Also
- Five stocks we like better than Biogen
- What is Insider Trading? What You Can Learn from Insider Trading
- Texas Roadhouse Stock Steering for New Highs This Year
- Retail Stocks Investing, Explained
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Do ETFs Pay Dividends? What You Need to Know
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.